Pemvidutide Promise | Explore pemvidutide's potential in MASH and obesity treatment, with unprecedented liver fat reduction and significant weight loss results |
Expanding Horizons | Delve into Altimmune's strategic expansion of pemvidutide applications to include alcohol use disorder and alcoholic liver disease |
Clinical Milestones | Anticipate key clinical trial outcomes, including the Phase 2b IMPACT trial for MASH, with top-line data expected in Q2 2025 |
Market Potential | Analyst price targets range from $12 to $28, with projected peak U.S. sales exceeding $2.5 billion for MASH indication alone |
Metrics to compare | ALT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipALTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −5.9x | −4.2x | −0.4x | |
PEG Ratio | −0.22 | 0.29 | 0.00 | |
Price/Book | 1.9x | 1.4x | 2.6x | |
Price / LTM Sales | 14,963.7x | 68.9x | 3.0x | |
Upside (Analyst Target) | - | 303.1% | 57.2% | |
Fair Value Upside | Unlock | 3.6% | 9.6% | Unlock |
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.